Bristol-Myers Squibb Stock Falls After Weak Guidance
Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025, compared with the $46.
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet its primary endpoint of recurrence-free survival when used as an additional treatment for patients with completely resected stage III-IV melanoma.
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi
Bristol-Myers' Opdualag fails Phase 3 melanoma study
Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing Opdualag,
Bristol-Myers Squibb Company (BMY) – Jim Cramer: “No, No, You Don’t Hold”
We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol sees sharper 2025 revenue drop after better-than-forecast Q4
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
BioSpace3d
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...
Bristol Steps Back From Diversity Pledge in Bow to Trump
Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so ...